Related Experiment Video
Updated: May 16, 2026
03:55
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
Thymomas and thymic carcinomas: prognostic factors and multimodal management
Bernhard Moser1, Margit Scharitzer1, Stefan Hacker2
1Medical University of Vienna-Thoracic Surgery Wien, Wien, Austria.
The Thoracic and Cardiovascular Surgeon
|December 11, 2012
Summary
Complete resection and Masaoka-Koga stage are key prognostic factors for thymic tumors. Multimodal treatment offers good patient care, but larger studies are needed for better understanding.
Area of Science:
- Thoracic surgery
- Oncology
- Tumor biology
Background:
- Thymomas and thymic carcinomas are rare malignancies.
- This study reports on resection and multimodal treatment outcomes from a Central European center (2001-2010).
Purpose of the Study:
- To identify prognostic factors in patients with thymomas and thymic carcinomas.
- To evaluate the effectiveness of multimodal treatment strategies.
Main Methods:
- Retrospective analysis of 84 resections in 72 patients over a 10-year period.
- Inclusion of patients with primary thymomas/thymic carcinomas and recurrences.
Main Results:
- Most patients presented with Masaoka-Koga stages I-IV.
- Complete resection was achieved in 88.9% of cases, with a 5-year survival rate of 87%.
- Decreased survival correlated with higher Masaoka-Koga stage (p=0.017) and incomplete resection (p<0.001).
Conclusions:
- Completeness of resection and Masaoka-Koga stage are significant prognostic indicators.
- Multidisciplinary treatment contributes to positive patient outcomes.
- Further research with larger patient cohorts is essential to advance the understanding and treatment of these rare tumors.
Related Concept Videos
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...